priors.science/reviews/targeted-therapy-lung-cancer

Targeted Therapy Lung Cancer

The current evidence on 13 claims, ordered from most established to most contested. Each score is the panel’s evidence certainty — how firmly the literature supports the claim as stated.

13claims tracked
116primary papers reviewed
2 Jun 2026latest evidence review
Weeklyre-scored against new papers
6 Established · 7 Likely · 0 Uncertain · 0 Doubtful  |  four-reviewer panel · PICO Framework
SignalClaimStandingEvidence certaintyCorpus
StableAlectinib first-line for ALK-positive non-small cell lung cancerALKEstablished92%10
StableOsimertinib first-line for EGFR-mutant lung cancerEGFREstablished91%12
StableAdjuvant osimertinib in resected EGFR-mutant lung cancerEGFREstablished91%9
StableLorlatinib third-line for ALK-positive lung cancerALKEstablished90%9
StableOsimertinib second-line for EGFR T790M resistanceEGFR ResistanceEstablished90%8
StableSelpercatinib for RET fusion non-small cell lung cancerMet RetEstablished88%9
StableLarotrectinib and entrectinib for NTRK fusion cancersBraf NtrkLikely84%9
StableSotorasib for KRAS G12C non-small cell lung cancerKrasLikely83%9
StableAdagrasib for KRAS G12C non-small cell lung cancerKrasLikely83%8
StableCapmatinib and tepotinib for MET exon 14 skipping lung cancerMet RetLikely81%9
StableAmivantamab for EGFR exon 20 insertion lung cancerEGFRLikely80%8
StableDabrafenib plus trametinib for BRAF V600E non-small cell lung cancerBraf NtrkLikely79%8
StableEGFR C797S-mediated osimertinib resistanceEGFR ResistanceLikely78%8
Standing — what the evidence certainty means
Established≥ 85%Strong, consistent evidence. Unlikely to change.
Likely65–84%Well supported, with some gaps or indirect evidence.
Uncertain40–64%Mixed or limited evidence. Genuinely open.
Doubtful15–39%Little support; the weight of evidence leans against it.
Refuted< 15%The evidence contradicts it — confidently false as stated.
Recent signal
strengthenedNew evidence raised the certainty since the last review.
weakenedNew evidence lowered the certainty since the last review.
newA claim added to the review recently.
StableNo recent change to the standing.
Standing, evidence certainty and corpus are always shown. The study behind each move, why it moved, and the sceptic’s challenge are delivered to subscribers.
Update your priors.Track this topic